Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in Combination With ZG006 With or Without Adebrelimab in ES-SCLC
NCT07892625Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2026
- Primary completion
- Sep 2028
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in small cell lung cancer (SCLC) (4 cohorts), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-Limiting Toxicities at 28 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07892625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892625.